This is an antibacterial drug-mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"), and their cell-wall-active treatments point at the inhibited node via target_mechanisms (analogous to how checkpoint inhibitor treatments link to "immune_checkpoint_blockade#Adaptive Immune Resistance"). Key conformance / treatment target: "Peptidoglycan Cross-Linking by Penicillin-Binding Proteins" (the beta-lactam target). The module is pathogen-process-centric: nodes are druggable steps in the conserved pathway, not individual drugs; a given antibiotic class maps to the step it inhibits. The two resistance nodes capture the gating knowledge that distinguishes "any cell-wall agent works" from real drug selection — intrinsic target absence in cell-wall-deficient organisms, and acquired protection of the pathway.
Peptidoglycan Precursor and Lipid II Synthesis
trigger
Cytoplasmic enzymes (MurA-MurF, Alr/Ddl) assemble the UDP-MurNAc-pentapeptide precursor terminating in a D-Ala-D-Ala dipeptide, which is transferred to the membrane lipid carrier to form lipid I and then lipid II — the universal substrate exported across the membrane for polymerization. Several antibiotic classes act here rather than at the final cross-linking step: fosfomycin inhibits the first committed enzyme MurA, D-cycloserine blocks D-Ala racemase and ligase, bacitracin blocks recycling of the lipid carrier, and glycopeptides (vancomycin, teicoplanin) bind and sequester the exposed D-Ala-D-Ala terminus of lipid II. Because glycopeptides recognize the substrate rather than an enzyme, their target can be remodeled to D-Ala-D-Lac in resistant enterococci and staphylococci.
Downstream
-
Peptidoglycan Cross-Linking by Penicillin-Binding Proteins
Polymerized glycan strands assembled from lipid II are cross-linked by PBP transpeptidases to form the mature sacculus.
Peptidoglycan Cross-Linking by Penicillin-Binding Proteins
therapeutic vulnerability
Glycosyltransferases polymerize the glycan backbone while DD-transpeptidases, also called penicillin-binding proteins (PBPs), cross-link the peptide stems to give peptidoglycan its load-bearing, mesh-like strength. This transpeptidation reaction is the target of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams), which are structural analogues of the D-Ala-D-Ala terminus and covalently acylate the PBP transpeptidase active-site serine, irreversibly inactivating it. This is the central, most widely exploited node of the module and the canonical conformance / treatment target for cell-wall-active therapy. Loss of cross-linking weakens the wall during active growth, which is why beta-lactams are most effective against dividing bacteria.
Used by disorders
Bejel
as Treponemal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Furunculosis
as Staphylococcal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Leptospirosis
as Leptospiral Peptidoglycan Cross-Linking (Beta-Lactam Target)
Ludwig's Angina
as Oral Flora Peptidoglycan Cross-Linking (Beta-Lactam Target)
Lyme Disease
as Borrelial Peptidoglycan Cross-Linking (Beta-Lactam Target)
Pinta
as Treponemal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Scarlet Fever
as Streptococcal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Whipple Disease
as Tropheryma Peptidoglycan Cross-Linking (Beta-Lactam Target)
Downstream
-
Cell Envelope Integrity Failure and Bactericidal Autolysis
When cross-linking is pharmacologically inhibited, the unbalanced action of peptidoglycan hydrolases ruptures the sacculus.
-
Acquired Resistance and Drug Inactivation
Bacteria can protect this step from inhibition by destroying the drug or altering the target enzyme, escaping cell-wall-active therapy.
Cell Envelope Integrity Failure and Bactericidal Autolysis
consequence
Peptidoglycan is the load-bearing layer that resists internal turgor pressure. When its synthesis is inhibited, the bacterium's own peptidoglycan hydrolases (autolysins) continue to cleave bonds in the sacculus without balanced resynthesis, leading to uncontrolled hydrolysis, rupture of the cell envelope, and lysis. Because this depends on active wall turnover, cell-wall inhibitors are bactericidal against growing cells and relatively inactive against dormant/stationary-phase organisms. The selectivity of this outcome — bacteria have peptidoglycan and human cells do not — underlies the high therapeutic index of beta-lactams and glycopeptides.
Acquired Resistance and Drug Inactivation
adaptive escape
Bacteria acquire resistance to cell-wall-active agents by three principal routes that map onto the steps above: enzymatic inactivation of the drug (beta-lactamases hydrolyze the beta-lactam ring before it reaches the PBP), modification or protection of the target enzyme (acquisition of a low-affinity PBP such as staphylococcal PBP2a, conferring methicillin resistance), and remodeling of the drug-binding substrate (replacement of the lipid II D-Ala-D-Ala terminus with D-Ala-D-Lac in vancomycin-resistant enterococci, abolishing glycopeptide binding). This node explains why a nominally "cell-wall-active" antibiotic can fail against a specific organism and why agent selection — narrow-spectrum penicillin vs beta-lactamase-stable cephalosporin/carbapenem vs anti-MRSA agent — is mechanism-driven.
Used by disorders
Furunculosis
as Methicillin Resistance via Low-Affinity PBP2a (MRSA)
Intrinsic Resistance in Cell-Wall-Deficient Organisms
intrinsic resistance
This module's entire mechanism presupposes a peptidoglycan target. Organisms of the class Mollicutes (Mycoplasma, Ureaplasma) lack a cell wall entirely, so beta-lactams, glycopeptides, and fosfomycin have no target and are intrinsically inactive regardless of dose. This is the clearest example of mechanism gating drug choice: such infections must be treated with agents acting on other targets (macrolides, tetracyclines, fluoroquinolones). Disorder entries for cell-wall-deficient pathogens should NOT declare conforms_to against the cross-linking node; this node documents the negative case and the reason cell-wall-active therapy is excluded.